- Long-term, daily proprietary gamma sensory stimulation was shown to be safe and well tolerated; treatment integrated well into subjects' daily lives. - Pivotal trials will launch this year to ...

As it plows ahead in its efforts to secure an FDA greenlight for its light- and sound-based neuromodulation device to treat Alzheimer’s disease, Cognito Therapeutics is taking an even closer look at ...

Riding high on early clinical trial results showing that its neuromodulation headset can improve memory and cognition and slow the deterioration of white matter in the brains of people with ...

New drugs for Alzheimer’s are finally coming onto the market after decades of failed attempts to slow its devastating progression. But startup Cognito Therapeutics is taking a drug-free approach to ...

Just as a new wave of approved drugs for Alzheimer’s disease reaches patients, medical device company Cognito Therapeutics has raised a fresh $35 million to advance its alternative treatment for the ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Cognito Therapeutics, a neurotechnology company advancing disease-modifying therapies to treat CNS diseases, today announced the appointment of Christian Howell as ...

Cognito Therapeutics has raised $50 million in funding as it seeks to advance treatments for an elusive target: cognitive decline. Cognito, based in Cambridge, Mass., is developing a headset that ...